ABBVIE INC (ABBV) Stock Fundamental Analysis

USA • New York Stock Exchange • NYSE:ABBV • US00287Y1091

223.43 USD
+4.41 (+2.01%)
At close: Feb 6, 2026
223.43 USD
0 (0%)
After Hours: 2/6/2026, 8:16:33 PM
Fundamental Rating

5

Overall ABBV gets a fundamental rating of 5 out of 10. We evaluated ABBV against 525 industry peers in the Biotechnology industry. ABBV has only an average score on both its financial health and profitability. ABBV is cheap, but on the other hand it scores bad on growth. ABBV also has an excellent dividend rating.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • ABBV had positive earnings in the past year.
  • ABBV had a positive operating cash flow in the past year.
  • ABBV had positive earnings in 4 of the past 5 years.
  • Of the past 5 years ABBV 4 years had a positive operating cash flow.
ABBV Yearly Net Income VS EBIT VS OCF VS FCFABBV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

1.2 Ratios

  • With an excellent Return On Assets value of 1.75%, ABBV belongs to the best of the industry, outperforming 88.95% of the companies in the same industry.
  • With an excellent Return On Invested Capital value of 15.64%, ABBV belongs to the best of the industry, outperforming 96.00% of the companies in the same industry.
  • ABBV had an Average Return On Invested Capital over the past 3 years of 13.67%. This is below the industry average of 18.12%.
  • The last Return On Invested Capital (15.64%) for ABBV is above the 3 year average (13.67%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 1.75%
ROE N/A
ROIC 15.64%
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
ABBV Yearly ROA, ROE, ROICABBV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 100

1.3 Margins

  • Looking at the Profit Margin, with a value of 3.94%, ABBV belongs to the top of the industry, outperforming 89.14% of the companies in the same industry.
  • ABBV's Profit Margin has declined in the last couple of years.
  • The Operating Margin of ABBV (33.05%) is better than 97.14% of its industry peers.
  • In the last couple of years the Operating Margin of ABBV has declined.
  • The Gross Margin of ABBV (71.16%) is better than 82.10% of its industry peers.
  • In the last couple of years the Gross Margin of ABBV has declined.
Industry RankSector Rank
OM 33.05%
PM (TTM) 3.94%
GM 71.16%
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
ABBV Yearly Profit, Operating, Gross MarginsABBV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60

4

2. Health

2.1 Basic Checks

  • ABBV has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
  • There is no outstanding debt for ABBV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ABBV Yearly Shares OutstandingABBV Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B
ABBV Yearly Total Debt VS Total AssetsABBV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50B 100B 150B

2.2 Solvency

  • ABBV has an Altman-Z score of 2.42. This is not the best score and indicates that ABBV is in the grey zone with still only limited risk for bankruptcy at the moment.
  • The Altman-Z score of ABBV (2.42) is better than 68.00% of its industry peers.
  • ABBV has a debt to FCF ratio of 3.49. This is a good value and a sign of high solvency as ABBV would need 3.49 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 3.49, ABBV belongs to the top of the industry, outperforming 92.38% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.49
Altman-Z 2.42
ROIC/WACC1.86
WACC8.41%
ABBV Yearly LT Debt VS Equity VS FCFABBV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20B 40B 60B

2.3 Liquidity

  • ABBV has a Current Ratio of 0.72. This is a bad value and indicates that ABBV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 0.72, ABBV is doing worse than 87.81% of the companies in the same industry.
  • ABBV has a Quick Ratio of 0.72. This is a bad value and indicates that ABBV is not financially healthy enough and could expect problems in meeting its short term obligations.
  • ABBV has a worse Quick ratio (0.60) than 88.57% of its industry peers.
Industry RankSector Rank
Current Ratio 0.72
Quick Ratio 0.6
ABBV Yearly Current Assets VS Current LiabilitesABBV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B 40B

2

3. Growth

3.1 Past

  • ABBV shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.19%.
  • ABBV shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -0.99% yearly.
EPS 1Y (TTM)-1.19%
EPS 3Y-10.33%
EPS 5Y-0.99%
EPS Q2Q%25.46%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%10.04%

3.2 Future

  • The Earnings Per Share is expected to grow by 14.29% on average over the next years. This is quite good.
  • Based on estimates for the next years, ABBV will show a small growth in Revenue. The Revenue will grow by 6.02% on average per year.
EPS Next Y45.22%
EPS Next 2Y27.48%
EPS Next 3Y21.41%
EPS Next 5Y14.29%
Revenue Next Year9.84%
Revenue Next 2Y8.84%
Revenue Next 3Y7.94%
Revenue Next 5Y6.02%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ABBV Yearly Revenue VS EstimatesABBV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20B 40B 60B 80B
ABBV Yearly EPS VS EstimatesABBV Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15 20

7

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 22.34, the valuation of ABBV can be described as rather expensive.
  • ABBV's Price/Earnings ratio is rather cheap when compared to the industry. ABBV is cheaper than 94.48% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 27.92. ABBV is around the same levels.
  • The Price/Forward Earnings ratio is 15.39, which indicates a correct valuation of ABBV.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of ABBV indicates a rather cheap valuation: ABBV is cheaper than 96.19% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 27.78, ABBV is valued a bit cheaper.
Industry RankSector Rank
PE 22.34
Fwd PE 15.39
ABBV Price Earnings VS Forward Price EarningsABBV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • ABBV's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. ABBV is cheaper than 95.05% of the companies in the same industry.
  • 95.62% of the companies in the same industry are more expensive than ABBV, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 20.06
EV/EBITDA 16.24
ABBV Per share dataABBV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 -40

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of ABBV may justify a higher PE ratio.
  • A more expensive valuation may be justified as ABBV's earnings are expected to grow with 21.41% in the coming years.
PEG (NY)0.49
PEG (5Y)N/A
EPS Next 2Y27.48%
EPS Next 3Y21.41%

7

5. Dividend

5.1 Amount

  • ABBV has a Yearly Dividend Yield of 3.16%. Purely for dividend investing, there may be better candidates out there.
  • ABBV's Dividend Yield is rather good when compared to the industry average which is at 1.12. ABBV pays more dividend than 99.05% of the companies in the same industry.
  • ABBV's Dividend Yield is rather good when compared to the S&P500 average which is at 1.81.
Industry RankSector Rank
Dividend Yield 3.16%

5.2 History

  • The dividend of ABBV is nicely growing with an annual growth rate of 7.72%!
  • ABBV has been paying a dividend for at least 10 years, so it has a reliable track record.
  • ABBV has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)7.72%
Div Incr Years11
Div Non Decr Years11
ABBV Yearly Dividends per shareABBV Yearly Dividends per shareYearly Dividends per share 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2 4 6

5.3 Sustainability

  • 489.69% of the earnings are spent on dividend by ABBV. This is not a sustainable payout ratio.
  • ABBV's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP489.69%
EPS Next 2Y27.48%
EPS Next 3Y21.41%
ABBV Yearly Income VS Free CF VS DividendABBV Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B
ABBV Dividend Payout.ABBV Dividend Payout, showing the Payout Ratio.ABBV Dividend Payout.PayoutRetained Earnings

ABBVIE INC

NYSE:ABBV (2/6/2026, 8:16:33 PM)

After market: 223.43 0 (0%)

223.43

+4.41 (+2.01%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-04
Earnings (Next)04-23
Inst Owners75.04%
Inst Owner Change-2.58%
Ins Owners0.05%
Ins Owner Change-0.57%
Market Cap394.89B
Revenue(TTM)N/A
Net Income(TTM)2.35B
Analysts78.38
Price Target252.53 (13.02%)
Short Float %1.25%
Short Ratio3.56
Dividend
Industry RankSector Rank
Dividend Yield 3.16%
Yearly Dividend6.24
Dividend Growth(5Y)7.72%
DP489.69%
Div Incr Years11
Div Non Decr Years11
Ex-Date01-16
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1.85%
Min EPS beat(2)0.95%
Max EPS beat(2)2.75%
EPS beat(4)4
Avg EPS beat(4)1.21%
Min EPS beat(4)0.02%
Max EPS beat(4)2.75%
EPS beat(8)7
Avg EPS beat(8)0.95%
EPS beat(12)9
Avg EPS beat(12)0.65%
EPS beat(16)11
Avg EPS beat(16)0.49%
Revenue beat(2)1
Avg Revenue beat(2)-0.08%
Min Revenue beat(2)-0.79%
Max Revenue beat(2)0.63%
Revenue beat(4)2
Avg Revenue beat(4)0.22%
Min Revenue beat(4)-0.79%
Max Revenue beat(4)1.23%
Revenue beat(8)4
Avg Revenue beat(8)0.31%
Revenue beat(12)5
Avg Revenue beat(12)-0.17%
Revenue beat(16)5
Avg Revenue beat(16)-0.74%
PT rev (1m)1.12%
PT rev (3m)4.07%
EPS NQ rev (1m)-20.87%
EPS NQ rev (3m)-21.02%
EPS NY rev (1m)-6.64%
EPS NY rev (3m)-5.77%
Revenue NQ rev (1m)0.15%
Revenue NQ rev (3m)0.05%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.35%
Valuation
Industry RankSector Rank
PE 22.34
Fwd PE 15.39
P/S 6.62
P/FCF 20.06
P/OCF 18.93
P/B N/A
P/tB N/A
EV/EBITDA 16.24
EPS(TTM)10
EY4.48%
EPS(NY)14.52
Fwd EY6.5%
FCF(TTM)11.14
FCFY4.98%
OCF(TTM)11.8
OCFY5.28%
SpS33.75
BVpS-1.49
TBVpS-52.38
PEG (NY)0.49
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 1.75%
ROE N/A
ROCE 20.86%
ROIC 15.64%
ROICexc 16.59%
ROICexgc 572.43%
OM 33.05%
PM (TTM) 3.94%
GM 71.16%
FCFM 33%
ROA(3y)5.07%
ROA(5y)5.21%
ROE(3y)80.76%
ROE(5y)70.31%
ROIC(3y)13.67%
ROIC(5y)12.68%
ROICexc(3y)15.06%
ROICexc(5y)13.91%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)17.54%
ROCE(5y)16.27%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y-1.81%
ROICexc growth 5Y-14.87%
OM growth 3Y-5.46%
OM growth 5Y-6.52%
PM growth 3Y-28.3%
PM growth 5Y-20.42%
GM growth 3Y0.39%
GM growth 5Y-1.92%
F-Score7
Asset Turnover0.45
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 3.49
Debt/EBITDA 2.39
Cap/Depr 14.25%
Cap/Sales 1.97%
Interest Coverage 250
Cash Conversion 74.59%
Profit Quality 838.33%
Current Ratio 0.72
Quick Ratio 0.6
Altman-Z 2.42
F-Score7
WACC8.41%
ROIC/WACC1.86
Cap/Depr(3y)9.59%
Cap/Depr(5y)10.06%
Cap/Sales(3y)1.45%
Cap/Sales(5y)1.5%
Profit Quality(3y)361.43%
Profit Quality(5y)328.91%
High Growth Momentum
Growth
EPS 1Y (TTM)-1.19%
EPS 3Y-10.33%
EPS 5Y-0.99%
EPS Q2Q%25.46%
EPS Next Y45.22%
EPS Next 2Y27.48%
EPS Next 3Y21.41%
EPS Next 5Y14.29%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%10.04%
Revenue Next Year9.84%
Revenue Next 2Y8.84%
Revenue Next 3Y7.94%
Revenue Next 5Y6.02%
EBIT growth 1Y27.38%
EBIT growth 3Y-5.38%
EBIT growth 5Y3.87%
EBIT Next Year-0.19%
EBIT Next 3Y15.91%
EBIT Next 5Y10.95%
FCF growth 1Y-20.4%
FCF growth 3Y-6.75%
FCF growth 5Y6.9%
OCF growth 1Y-18.24%
OCF growth 3Y-6.19%
OCF growth 5Y7.14%

ABBVIE INC / ABBV FAQ

Can you provide the ChartMill fundamental rating for ABBVIE INC?

ChartMill assigns a fundamental rating of 5 / 10 to ABBV.


What is the valuation status of ABBVIE INC (ABBV) stock?

ChartMill assigns a valuation rating of 7 / 10 to ABBVIE INC (ABBV). This can be considered as Undervalued.


Can you provide the profitability details for ABBVIE INC?

ABBVIE INC (ABBV) has a profitability rating of 6 / 10.


Can you provide the PE and PB ratios for ABBV stock?

The Price/Earnings (PE) ratio for ABBVIE INC (ABBV) is 22.34 and the Price/Book (PB) ratio is -149.46.


What is the expected EPS growth for ABBVIE INC (ABBV) stock?

The Earnings per Share (EPS) of ABBVIE INC (ABBV) is expected to grow by 45.22% in the next year.